Ingrezza (Valbenazine) for Tardive Dyskinesia (TD)What is Ingrezza?
Ingrezza (valbenazine) is a medication specifically designed to treat tardive dyskinesia (TD), a condition characterized by involuntary, repetitive movements, often resulting from long-term use of certain psychiatric medications. Please read our blog here for more on what tardive dyskinesia is, including a video reference.
What Percentage of Patients Benefit?
Clinical trials have shown that approximately 70% of patients experience a significant reduction in TD symptoms when taking Ingrezza.
Starting vs. Maintenance Dosing
Starting Dose: The recommended starting dose is 40 mg once daily for the first week.
Maintenance Dose: After the first week, the dose is typically increased to 80 mg once daily, which is the usual maintenance dose. Your doctor may adjust the dose based on your response and tolerability.
What Time to Take It
Ingrezza should be taken once daily, with or without food. It is generally recommended to take it at the same time each day to maintain consistent levels in your body.
Potential Side Effects
Common side effects of Ingrezza may include:
Sleepiness or drowsiness
Fatigue
Dry mouth
Constipation
Less common but more serious side effects include changes in heart rhythm. If you experience symptoms such as dizziness, palpitations, or fainting, contact your healthcare provider immediately.
Potential Contraindications
Ingrezza may not be suitable for everyone. Contraindications include:
Hypersensitivity to valbenazine or any of its components
Pre-existing heart conditions (due to the risk of QT prolongation)
Liver impairment
Always discuss your full medical history with your doctor before starting Ingrezza.
FDA Approval Information
Ingrezza was approved by the FDA in April 2017 for the treatment of tardive dyskinesia. This approval was based on evidence from clinical trials demonstrating its efficacy and safety in reducing TD symptoms.
Off-Label Benefits
Research is ongoing, but some studies suggest that Ingrezza might have benefits beyond treating TD, including potential improvements in conditions like Huntington's disease chorea. However, these uses are off-label and should be discussed with your healthcare provider.
